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1  | WHAT IS KNOWN AND OBJEC TIVE
Several drugs prescribed for common indications have anticholin‐
ergic properties.1 Anticholinergic properties may be desired in the 
management of certain conditions (eg, urinary incontinence and 
Parkinson’s disease). Numerous common drugs in different thera‐
peutic groups may have anticholinergic properties, and identifying 
these properties may be challenging. Diabetes has been associated 
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Summary
What is known and objective: Anticholinergic drug use has been associated with a 
risk of central and peripheral adverse effects. There is a lack of information on an‐
ticholinergic drug use in persons with diabetes. The aim of this study is to investigate 
anticholinergic drug use and the association between anticholinergic drug use and 
self‐reported symptoms in older community‐dwelling persons with and without 
diabetes.
Methods: The basic population was comprised of Finnish community‐dwelling pri‐
mary care patients aged 65 and older. Persons with diabetes were identified accord‐
ing to the ICD‐10 diagnostic codes from electronic patient records. Two controls 
adjusted by age and gender were selected for each person with diabetes. This cross‐
sectional study was based on electronic primary care patient records and a struc‐
tured health questionnaire. The health questionnaire was returned by 430 (81.6%) 
persons with diabetes and 654 (73.5%) persons without diabetes. Data on prescribed 
drugs were obtained from the electronic patient records. Anticholinergic drug use 
was measured according to the Anticholinergic Risk Scale. The presence and strength 
of anticholinergic symptoms were asked in the health questionnaire.
Results and discussion: The prevalence of anticholinergic drug use was 8.9% in the 
total study cohort. There were no significant differences in anticholinergic drug use 
between persons with and without diabetes. There was no consistent association 
between anticholinergic drug use and self‐reported symptoms.
What is new and conclusion: There is no difference in anticholinergic drug use in 
older community‐dwelling persons with and without diabetes. Anticholinergic drug 
use should be considered individually and monitored carefully.
K E Y W O R D S
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with conditions for which drugs with anticholinergic properties may 
be prescribed (eg, depression and neuropathic pain).2,3
Anticholinergic drugs expose older people to adverse drug ef‐
fects.4 Older people are known to be particularly at increased risk of 
anticholinergic adverse effects due to a decrease in central choliner‐
gic receptors and an increase in blood‐brain barrier permeability.5,6 
Anticholinergic adverse drug effects may occur peripherally (eg, 
dry mouth, dry eyes and constipation) or centrally (eg, drowsiness, 
dizziness and confusion).4 Furthermore, anticholinergic drug use 
has been associated with both cognitive and functional decline.7‐9 
Anticholinergic drug use in older people may lead to further adverse 
health outcomes, including hospital admissions and more visits to 
general practitioners.10
There is limited previous research on anticholinergic drug use 
in specific populations. Anticholinergic drug use has been evalu‐
ated, for example in persons with cognitive impairment,7 schizo‐
phrenia11 and Parkinson’s disease.12,13 There are a few previous 
studies investigating anticholinergic drug use in persons with 
diabetes.14,15 These studies have focused on management of 
overactive bladder syndrome. Anticholinergic drug use has been 
associated with a higher prevalence of diabetes in a previous 
Finnish study.16
Diabetes has been associated with polypharmacy and comorbid‐
ities.17,18 In particular, people with type 2 diabetes are at a greater 
risk of polypharmacy.19 Polypharmacy in people with diabetes can 
be justifiable. Nevertheless, polypharmacy has been associated with 
anticholinergic drug use and a greater anticholinergic burden.20‐23 
Furthermore, diabetes has been associated with possible blood‐
brain barrier dysfunction, which may increase the risk of central ad‐
verse effects.24‐26
The aim of this study was to evaluate anticholinergic drug use 
and its association with self‐reported symptoms among community‐
dwelling older people with and without diabetes.
2  | METHODS
2.1 | Study population
This cross‐sectional study was conducted in the communi‐
ties of Suonenjoki and Rautalampi in Eastern Finland. The total 
population of the district was 10 793, and the basic population 
(N = 3093) was comprised of community‐dwelling primary care 
patients aged 65 and older. Persons with diabetes (N = 540) were 
identified from primary care electronic patient records according 
to diagnostic codes E10 and E11 of the International Classification 
of Diagnoses (ICD‐10).27 The cohort included 12 subjects with 
type 1 diabetes. Two controls adjusted by age and gender were 
selected for each person with diabetes. A structured health ques‐
tionnaire was mailed once to 527 persons with diabetes and 890 
controls in 2015 (August‐September). This study is a part of the 
ISDM study, which has been described previously elsewhere by 
Karjalainen et  al.28
2.2 | Study design
2.2.1 | Data source
Data on prescribed drugs were obtained from the primary care elec‐
tronic patient records (Pegasos®, CGI Suomi Ltd, Helsinki, Finland). 
Regular medications (daily or at regular intervals) were consid‐
ered. Medications were categorized according to the World Health 
Organization (WHO) Anatomical Therapeutic Chemical (ATC) clas‐
sification system codes.29
2.2.2 | Anticholinergic burden
The Anticholinergic Risk Scale (ARS) created by Rudolph et  al is 
one of several tools available for identifying a cumulative anticho‐
linergic burden that may lead to adverse effects.4,30 In this study, 
the anticholinergic burden was quantified using the ARS, which has 
been previously applied in numerous studies.30 The ARS is based on 
a literature review and expert opinion.4 The review encompassed 
the 500 most frequently prescribed medications within the Veterans 
Affairs Boston Healthcare System, excluding topical, ophthalmic, 
otologic and inhaled medication preparations. Medications were 
classified into four categories from 0 to 3 according to their anticho‐
linergic activity (0, limited or none; 1, moderate; 2, strong; 3, very 
strong). At present, 40 of the 49 anticholinergic medications listed in 
the ARS are available in Finland.31
2.2.3 | Measurements and tools
A structured health questionnaire was used to obtain data on back‐
ground variables (sex, age, education years, living arrangements), 
self‐rated health, health‐related quality of life, exercise, depressive 
symptoms, consumption of alcohol, smoking, comorbidities and self‐
reported symptoms.
Self‐rated health was assessed based on a numerical rating scale 
from 1 to 5 (excellent‐poor). Health‐related quality of life was as‐
sessed using the EuroQol EQ‐5D questionnaire.32 The frequency, ef‐
ficiency and duration of exercise were assessed based on Kasari’s FIT 
Index.33 Depressive symptoms were evaluated using the Geriatric 
Depression Scale (GDS‐15).34 Alcohol consumption was measured 
based on the Alcohol Use Disorders Identification Test (AUDIT‐C).35 
History and frequency of smoking were asked. Comorbidity was 
defined according to a list of common chronic diseases (mental 
disorder, Parkinson’s disease, dementia, musculoskeletal disorder, 
cardiovascular disease, cancer, chronic obstructive pulmonary dis‐
ease, asthma) and calculated using the Charlson Comorbidity Index 
(CCI).36
In one part of the questionnaire, the participants were asked to 
assess whether they had experienced various symptoms: dry eyes, 
dry mouth, constipation, gastrointestinal dysfunction or dizziness. 
These symptoms present typical anticholinergic adverse effects in 
older people.4 The participants ranked the severity of each symptom 
using a numerical rating scale from 0 to 10.
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2.3 | Ethics approval
The study was approved by the Inner Savo Health Care Federation 
of Municipalities (61 A/2015). The study protocol of the ISDM 
(Inner Savo Diabetes Mellitus) study was approved by the Research 
Ethics Committee of the Northern Savo Hospital District, Kuopio, 
Finland (256/2015). The study was conducted in accordance with 
the Helsinki’s Declaration. The health questionnaire included an 
information letter explaining the use of the data, and returning 
the questionnaire was voluntary. The autonomy of the research 
subjects was respected, and only anonymous data were analysed. 
No harm to the subjects was possible, and the confidentiality of 
the subjects and research data was protected.
2.4 | Statistical analysis
Descriptive statistics include means and SDs (standard deviations) 
for continuous variables and numbers and percentages for categori‐
cal variables. Statistical comparisons were made using analysis of 
variance (ANOVA) and logistic models with covariates when ap‐
propriate. Models included groups (diabetes and the ARS) and their 
interaction. The stata 15.0, StataCorp LP (College Station, TX, USA) 
statistical package, was used for the analyses.
3  | RESULTS AND DISCUSSION
The health questionnaire was returned by 430 persons with diabetes 
(81.6%) and 654 controls (73.5%). Females constituted 50.9% of the 
respondents with diabetes and 54.4% of the respondents without dia‐
betes. The demographic characteristics of the study cohort according 
to anticholinergic drug use are presented in Table 1.
Persons with diabetes had a higher mean age, fewer years of educa‐
tion, a lower EQ‐5D score, a lower Kasari’s FIT Index, mobility aids more 
often, a higher CCI (excluding diabetes), dementia more often, cardiovas‐
cular disease more often and a higher mean number of drugs compared 
with persons without diabetes. Persons using at least one anticholinergic 
drug were more often female, had a higher mean age, were more often 
TA B L E  1   Descriptive characteristics of the study population
No diabetes Diabetes P‐values for effects
ARS 0 
N = 599
ARS >0 
N = 55
ARS 0 
N = 389
ARS >0 
N = 41 Diabetes ARS Interaction
Female, (%) 318 (53.1) 38 (69.1) 193 (49.6) 26 (63.4) 0.39 0.006 0.80
Age, mean (SD) 74 (6) 75 (7) 75 (7) 77 (8) 0.024 0.009 0.23
Education, y, mean (SD) 9.9 (3.2) 9.9 (3.3) 9.3 (3.0) 9.2 (3.0) 0.006 0.89 0.64
Living alone, n (%) 184 (30.7) 24 (43.6) 136 (35.0) 20 (48.8) 0.36 0.010 0.97
Good self‐rated health (1, 2, 3), n (%) 343 (57.3) 21 (38.2) 165 (42.4) 13 (31.7) 0.052 0.007 0.49
EQ‐5D, mean (SD) 0.8 (0.2) 0.7 (0.2) 0.7 (0.2) 0.6 (0.3) 0.004 <0.001 0.80
No mobility aids, n (%) 502 (83.8) 45 (81.8) 279 (71.7) 20 (48.8) <0.001 0.024 0.090
Kasari’s FIT Index, mean (SD) 40 (22) 37 (24) 30 (22) 24 (16) <0.001 0.084 0.51
GDS‐15, mean (SD) 2.5 (2.7) 3.6 (4.0) 3.3 (3.0) 4.3 (3.5) 0.058 0.012 0.93
Smoking, n (%) 63 (10.5) 4 (7.3) 22 (5.7) 1 (2.4) 0.12 0.27 0.69
AUDIT‐C, mean (SD) 2.0 (2.1) 2.0 (2.1) 1.9 (2.2) 1.4 (1.9) 0.084 0.27 0.36
CCI, mean (SD)
Total 0.4 (0.7) 0.5 (0.7) 1.7 (1.0) 1.9 (1.1) <0.001 0.051 0.44
Excluding diabetes 0.4 (0.7) 0.5 (0.7) 0.6 (0.9) 0.7 (1.0) 0.011 0.14 0.65
Mental disorder, n (%) 8 (1.3) 4 (7.3) 14 (3.6) 4 (9.8) 0.12 0.001 0.42
Parkinson’s disease, n (%) 2 (0.3) 3 (5.5) 5 (1.3) 2 (4.9) 0.32 <0.001 0.24
Dementia, n (%) 27 (4.5) 3 (5.5) 27 (6.9) 7 (17.1) 0.026 0.12 0.29
Musculoskeletal disorder, n (%) 257 (42.9) 34 (61.8) 206 (53.0) 29 (70.7) 0.081 <0.001 0.99
Cardiovascular disease, n (%) 337 (56.3) 36 (65.5) 302 (77.6) 34 (82.9) <0.001 0.17 0.92
Cancer C00‐97 (malign tumour), n (%) 52 (8.7) 1 (1.8) 26 (6.7) 2 (4.9) 0.32 0.25 0.54
COPD/asthma, n (%) 44 (7.3) 9 (16.4) 42 (10.8) 7 (17.1) 0.43 0.016 0.53
Number of drugs (excluding ATC codes P, 
D, J, V), mean (SD)
2.0 (2.6) 6.0 (3.3) 3.6 (3.1) 7.0 (4.4) 0.003 <0.001 0.42
ATC codes: P, antiparasitic products, insecticides and repellents; D, dermatologicals; J, anti‐infectives for systemic use; V, various (eg, allergens, diag‐
nostic agents)27; ARS, Anticholinergic Risk Scale2; AUDIT‐C, alcohol use disorders identification test33; CCI, Charlson Comorbidity Index34; COPD, 
chronic obstructive pulmonary disease; EQ‐5D; EuroQol EQ‐5D questionnaire30; GDS‐15, Geriatric Depression Scale.32
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living alone, less frequently had good self‐rated health, had a lower EQ‐5D 
score, more often had mobility aids, had higher mean GDS‐15 scores, 
more often had a mental disorder, Parkinson’s disease, a musculoskeletal 
disorder, COPD or asthma and had a higher mean number of drugs. There 
was no interaction between the groups (diabetes and the ARS).
3.1 | Anticholinergic drug use
The use of anticholinergic drugs is described in detail in Table 2. The 
prevalence of anticholinergic drug use was 8.9% in the total study 
cohort. Anticholinergic drug use was not associated with having dia‐
betes. Forty‐one (9.5%) persons with diabetes had at least one ARS 
score, whereas 55 (8.4%) of the controls scored at least one. The 
highest level of anticholinergic burden was five scores (four of the 
persons without diabetes).
The anticholinergic drugs used in the cohort are shown in Table 3. 
The most frequently used anticholinergic drug groups were psycho‐
analeptics (32.1% of total anticholinergic use), antihistamines for 
systemic use (20.8%) and psycholeptics (19.8%) among both persons 
with and without diabetes. Twenty‐four anticholinergic drugs were 
identified. The most frequently used anticholinergic drugs in the total 
cohort were mirtazapine (12.3%), cetirizine (12.3%), amitriptyline 
with psycholeptics (10.4%), amitriptyline (8.5%) and loratadine (8.5%).
3.2 | Anticholinergic drug use and self‐
reported symptoms
There was no consistent association between anticholinergic drug 
use and self‐reported symptoms. Anticholinergic drug use was asso‐
ciated with a higher risk of constipation and dizziness in both groups 
when adjusted by age, gender, years of education, GDS‐15, smoking, 
alcohol consumption and CCI (excluding diabetes). In addition to this, 
anticholinergic drug use was associated with a higher risk of dry eyes 
in the group with diabetes and a higher risk of dry mouth, gastroin‐
testinal dysfunction and fatigue in the control group (in the adjusted 
model). The results in the adjusted model are shown in Figure 1.
4  | DISCUSSION
One‐tenth of this older community‐dwelling Finnish population 
used anticholinergic drugs, and anticholinergic drug use was not 
associated with having diabetes. The results suggest that the use 
of anticholinergic drugs in the study population is relatively low. In 
previous Finnish studies, the prevalence of anticholinergic drug use 
has varied from 16% among community dwellers to 55% among per‐
sons living in long‐term wards (when measured using the ARS).20,37,38 
There are no known previous studies investigating the prevalence of 
anticholinergic drug use in persons with diabetes, whereupon it is 
not possible to compare the results with previous findings in similar 
populations. Persons with diabetes may be even better monitored 
because the healthcare system provides diabetes nurse services, for 
example. However, one previous Finnish study found diabetes to be 
more common in anticholinergic drug users than in non‐users among 
home‐dwelling older people, which shows that the association is un‐
clear.16 The disparity of the results may arise from differences be‐
tween the study populations and anticholinergic drug scales.
Psychoanaleptics and psycholeptics composed approximately 
half of the anticholinergic drug use in the study cohort. These find‐
ings are mostly in line with a previous Finnish study using the ARS, 
which found risperidone, mirtazapine, olanzapine and hydroxyzine 
as the most frequently used anticholinergic drugs among persons 
living in long‐term wards.37 Low‐dose administration of mirtazapine 
in the management of chronic insomnia is mentioned in the Finnish 
Good Care Guidelines.39 Mirtazapine might have been chosen as a 
safer alternative to benzodiazepines or z‐drugs.
In this study, we investigated the association between anticho‐
linergic drug use and self‐reported symptoms that may indicate ad‐
verse drug effects. There was no consistent association between 
anticholinergic drug use and symptoms evaluated although the ARS, 
and the association with anticholinergic symptoms has been val‐
idated.4 Similarly with our study, a previous Finnish study did not 
find a consistent association between anticholinergic drug use and 
adverse drug events.20 Anticholinergic drug use was defined accord‐
ing to the ARS, but the adverse outcomes differed from those in our 
study (eg, functional capacity and cognition). Another Finnish study 
using the ARS did not find an association between anticholinergic 
drug use and dry mouth or constipation.38 Studies using different 
anticholinergic drug scales have shown dry mouth and constipation 
to be more prevalent among anticholinergic drug users.23,40 We 
were not able to confirm the cause of symptoms; the symptoms may 
be both drug‐related and disease‐related.
One of the strengths of this study was the high response rate of 
the health questionnaire and the high validity of the data collection. 
Rudolph’s Anticholinergic Risk 
Scale (score) No diabetes, n (%) Diabetes, n (%) Total, n (%)
0 599 (91.6) 389 (90.5) 988 (91.1)
1 18 (2.8) 12 (2.8) 30 (2.8)
2 14 (2.1) 15 (3.5) 29 (2.7)
3 19 (2.9) 12 (2.8) 31 (2.9)
4 0 (0.0) 2 (0.5) 2 (0.2)
5 4 (0.6) 0 (0.0) 4 (0.4)
TA B L E  2   Anticholinergic drug use 
among persons with and without diabetes
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The health questionnaire provided thorough information on back‐
ground variables, which enables comparison of the groups and 
adjustment for several potential confounders. The ARS has been 
validated in a veteran’s population, and higher ARS scores have been 
associated with anticholinergic adverse effects.4 Apart from that, 
the ARS has been previously applied to other studies evaluating the 
TA B L E  3   Anticholinergic drugs used by persons with and without diabetes
Anticholinergic drug (ATC code) No diabetes, n (%) Diabetes, n (%) Total, n (%)
Cetirizine (R06AE07) 5 (8.1) 8 (18.2) 13 (12.3)
Mirtazapine (N06AX11) 8 (12.9) 5 (11.4) 13 (12.3)
Amitriptyline and psycholeptics (N06CA01) 8 (12.9) 3 (6.8) 11 (10.4)
Amitriptyline (N06AA09) 5 (8.1) 4 (9.1) 9 (8.5)
Loratadine (R06AX13) 7 (11.3) 2 (4.6) 9 (8.5)
Tizanidine (M03BX02) 5 (8.1) 2 (4.6) 7 (6.6)
Quetiapine (N05AH04) 1 (1.6) 5 (11.4) 6 (5.7)
Hydroxyzine (N05BB01) 1 (1.6) 3 (6.8) 4 (3.8)
Levodopa and decarboxylase inhibitor (N04BA02) 3 (4.8) 1 (2.3) 4 (3.8)
Olanzapine (N05AH03) 2 (3.2) 2 (4.6) 4 (3.8)
Pramipexole (N04BC05) 4 (6.5) 0 (0.0) 4 (3.8)
Risperidone (N05AX08) 3 (4.8) 1 (2.3) 4 (3.8)
Loperamide (A07DA03) 2 (3.2) 1 (2.3) 3 (2.8)
Pseudoephedrine, combinations (R01BA52) 2 (3.2) 1 (2.3) 3 (2.8)
Metoclopramide (A03FA01) 0 (0.0) 2 (4.6) 2 (1.9)
Oxybutynin (G04BD04) 1 (1.6) 1 (2.3) 2 (1.9)
Baclofen (M03BX01) 0 (0.0) 1 (2.3) 1 (0.9)
Clozapine (N05AH02) 0 (0.0) 1 (2.3) 1 (0.9)
Levodopa, decarboxylase inhibitor and COMT inhibitor (N04BA03) 0 (0.0) 1 (2.3) 1 (0.9)
Perphenazine (N05AB03) 1 (1.6) 0 (0.0) 1 (0.9)
Prochlorperazine (N05AB04) 1 (1.6) 0 (0.0) 1 (0.9)
Ranitidine (A02BA02) 1 (1.6) 0 (0.0) 1 (0.9)
Selegiline (N04BD01) 1 (1.6) 0 (0.0) 1 (0.9)
Trazodone (N06AX05) 1 (1.6) 0 (0.0) 1 (0.9)
Total 62 (100.0) 44 (100.0) 106 (100.0)
ATC, anatomical therapeutic chemical.
F I G U R E  1   Self‐reported symptoms 
among persons with and without diabetes 
(adjusted model). ARS, Anticholinergic 
Risk Scale; NRS, numerical rating scale
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association between anticholinergic medications and adverse drug 
effects.20,38 Additionally, not only the presence but also the strength 
of symptoms was determined in this study.
This study has a few limitations. The study cohort was geo‐
graphically restricted and represents the population of one pri‐
mary care district in a semirural area in Eastern Finland. The 
findings cannot be directly generalized to other populations. 
Persons with diabetes represent persons able to live at home, 
which makes survival bias possible. Because of the cross‐sec‐
tional design of the study, it was not possible to prove any causal 
relationship between anticholinergic drug use and self‐reported 
symptoms. Although we obtained extensive information on back‐
ground variables, only diagnosis of diabetes was confirmed from 
electronic patient records; other comorbidities were self‐re‐
ported. We were not able to determine the onset or progression 
of diabetes exactly, but we can presume that the participants 
represent patients with a substantially long history of diabe‐
tes, since the study recruitment was performed according to 
an established diagnosis of diabetes 3 months before the ques‐
tionnaire was sent. Lastly, self‐reporting may underestimate ad‐
verse effects compared with adverse effects noted in the clinical 
examination.41
5  | WHAT IS NE W AND CONCLUSION
There is no difference in anticholinergic drug use in older commu‐
nity‐dwelling persons with and without diabetes. There is no consist‐
ent association between anticholinergic drug use and self‐reported 
anticholinergic symptoms. Further studies are needed to confirm the 
impact of anticholinergic drugs on experienced symptoms in differ‐
ent subpopulations.
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